References
- Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting #70 brief document. [cited 2022 Feb 25]. Available from: www.fdagov/media/151599/download
- Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018 Mar 16;8:87–104. PubMed PMID: 29326962; PubMed Central PMCID: PMCPMC5758940.
- Flotte TR. Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther. 2020;31(7–8):398–399.
- Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357–2365. PubMed PMID: 22149959; PubMed Central PMCID: PMCPMC3265081.
- Paulk N. Gene therapy: it’s time to talk about high-dose AAV. Genet Eng Biotechnol News. 2020;40(9):14–16.
- Ronzitti G, Gross DA, Mingozzi F. Human immune responses to Adeno-Associated Virus (AAV) vectors. Front Immunol. 2020;11:670. PubMed PMID: 32362898.
- Muhuri M, Maeda Y, Ma H, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021 Jan 4;131(1). PubMed PMID: 33393506. DOI: 10.1172/JCI143780.
- Watkins PB. Liver injury due to drugs and viruses: mechanistic similarities and implications for AAV gene therapy. Clin Pharmacol Ther. 2021 Dec 15; PubMed PMID: 34910298. DOI: 10.1002/cpt.2500.
- Philippidis A. Fourth boy dies in trial of Astellas gene therapy candidate. Genet Eng Biotechnol News 2021. (accessed 2022 Feb 25. https://www.genengnews.com/news/fourth-boy-dies-in-trial-of-astellas-gene-therapy-candidate/.
- Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy a case series. J Pediatr. 2021 Apr;231:265–268. PubMed PMID: 33259859.
- Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021 Feb 3;29(2):464–488. PubMed PMID: 33309881; PubMed Central PMCID: PMCPMC7854298.
- Mullard A. Gene therapy community grapples with toxicity issues, as pipeline matures. Nature. 2021;20:804–805.
- [cited 2022 Feb 25]. https://www.cureduchenne.org/partner-news/a-message-from-pfizer-on-our-dmd-clinical-program/
- [cited 2022 Feb 25]. https://endpts.com/one-of-pfizers-duchenne-gene-therapy-trials-put-on-hold-in-wake-of-patient-death-as-high-dose-aav-concerns-still-cloud-field/
- Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001Sep;817:1343–1346. PubMed PMID: 11571571.
- Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015Feb;1252:870–880. PubMed PMID: 25607839; PubMed Central PMCID: PMCPMC4319425.
- Hordeaux J, Buza EL, Dyer C, et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gene Ther. 2020Aug;3115–16:808–818. PubMed PMID: 32845779.
- Nguyen GN, Everett JK, Kafle S, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021Jan;391:47–55. PubMed PMID: 33199875; PubMed Central PMCID: PMCPMC7855056.
- [cited 2022 Feb 25]. http://uniqure.com/PR_HCC%20Investigation%20Findings%20_3_29_21_FINAL.pdf
- [cited 2022 Feb 25]. https://investors.biomarin.com/2021-09-06-U-S-FDA-Placed-a-Clinical-Hold-on-BMN-307-Phearless-Phase-1-2-Gene-Therapy-Study-in-Adults-with-PKU-Based-on-Interim-Pre-clinical-Study-Findings
- Hordeaux J, Buza EL, Jeffrey B, et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med. 2020 Nov 11;12(569). PubMed PMID: 33177182. DOI: 10.1126/scitranslmed.aba9188.
- Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018Mar;293:285–298. PubMed PMID: 29378426; PubMed Central PMCID: PMCPMC5865262.
- Hamilton BA, Wright JF. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 2021;12:675897. PubMed PMID: 34084173; PubMed Central PMCID: PMCPMC8168460.
- [cited 2022 Feb 25]. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-srp-9001-shows-sustained-functional
- Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7827–7832. PubMed PMID: 18511559; PubMed Central PMCID: PMCPMC2402387.
- Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. PubMed PMID: 32042148, Nat Rev Genet. 2020 Apr;21(4):255–272.
- George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017 Dec 7;377(23):2215–2227. PubMed PMID: 29211678; PubMed Central PMCID: PMCPMC6029626.
- Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011Nov;1911:2084–2091. PubMed PMID: 21629225; PubMed Central PMCID: PMCPMC3222518.
- Leborgne C, Barbon E, Alexander JM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020Jul;267:1096–1101. PubMed PMID: 32483358.
- Kuranda K, Jean-Alphonse P, Leborgne C, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Invest. 2018 Dec 3;128(12):5267–5279. PubMed PMID: 30352429; PubMed Central PMCID: PMCPMC6264647.
- Majowicz A, Nijmeijer B, Lampen MH, et al. Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev. 2019 Sep 13;14:27–36. PubMed PMID: 31276009; PubMed Central PMCID: PMCPMC6586596.
- Corti M, Cleaver B, Clement N, et al. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev. 2015Sep;263:185–193. PubMed PMID: 26390092; PubMed Central PMCID: PMCPMC4606909.
- Meliani A, Boisgerault F, Hardet R, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018 Oct 5;9(1):4098. PubMed PMID: 30291246; PubMed Central PMCID: PMCPMC6173722.
- Ilyinskii PO, Roy CJ, LePrevost J, et al. Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles. Front Immunol. 2021;12:637469. PubMed PMID: 34113339; PubMed Central PMCID: PMCPMC8186318.
- Hosel M, Huber A, Bohlen S, et al. Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors. Hepatology. 2017Jul;661:252–265. PubMed PMID: 28318036; PubMed Central PMCID: PMCPMC5518300.
- Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013Nov-Dec;40(6):463–471. PubMed PMID: 23829164.